LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

August 19, 2025 | Last Trade: US$0.97 0.06 -6.12

BRANFORD, Conn. / Aug 19, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place at the Lotte New York Palace Hotel, September 8-10, 2025.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, September 9, 2025 and Jeff Hawkins will participate in a fireside chat on the same day at 10:00 AM Eastern Time.

A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page